Trials / Completed
CompletedNCT05292040
A Study of LY3857210 in Healthy Participants
An Adaptive Design, Phase 1, Open-label Study to Investigate Receptor Occupancy in Brain After Single Oral Doses of LY3857210 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]-LY3818850 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \[18F\]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3857210 | Administered orally. |
Timeline
- Start date
- 2022-03-17
- Primary completion
- 2022-12-14
- Completion
- 2022-12-14
- First posted
- 2022-03-23
- Last updated
- 2023-03-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05292040. Inclusion in this directory is not an endorsement.